# NCT03076554 (NCT03076554)

> A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

No report yet. It can be ordered.

- Drugs tested: avelumab
- Indication: thymoma and thymic carcinoma after platinum-based chemotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03076554
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Thymoma; Thymic Carcinoma
- Interventions: Avelumab
- Enrollment: 56
- Primary outcome: Safety and tolerability of Avelumab based on NCI-CTCAE v4.0
- Primary outcome: Objective Response Rate (ORR) based on RECIST 1.1 criteria

## Indexed commentary on NCT03076554 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03076554